Celldex Therapeutics, Inc.: Form 10-K for the period ended Dec 31, 2012
Filed with the SEC on Mar 8, 2013 and accepted by EDGAR at Mar 8, 2013, 12:53 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2012-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2012-10-01 to 2012-12-31 | $3.6m | us-gaap:Revenues |
| Revenue | 12 months2012-01-01 to 2012-12-31 | $11.2m | us-gaap:Revenues |
| Research and development | 12 months2012-01-01 to 2012-12-31 | $47.4m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2012-01-01 to 2012-12-31 | −$58.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2012-01-01 to 2012-12-31 | $1.6m | us-gaap:InterestExpense |
| Income tax | 12 months2012-01-01 to 2012-12-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2012-10-01 to 2012-12-31 | −$16.8m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Net income | 12 months2012-01-01 to 2012-12-31 | −$59.1m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Diluted EPS | 3 months2012-10-01 to 2012-12-31 | −$0.27 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 12 months2012-01-01 to 2012-12-31 | −$1.02 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 12 months2012-01-01 to 2012-12-31 | −$49.8m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 12 months2012-01-01 to 2012-12-31 | $303.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2012-12-31 | $24.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2012-12-31 | $85.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2012-12-31 | $125.5m | us-gaap:Assets |
| Current liabilities | At period end2012-12-31 | $17.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2012-12-31 | $29.8m | us-gaap:Liabilities |
| Shareholders' equity | At period end2012-12-31 | $95.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001047469-13-002403. Last ingested by Listed: Nov 5, 2026, 19:04 ET. Listed shows no prices and gives no investment advice.